Addition of CRISPR and RNAi offerings to complement PerkinElmer’s life sciences and applied genomics solutions, with future opportunities to improve cell based discovery for precision medicine WALTHAM, Mass. –(BUSINESS WIRE)–Nov. 2, 2020– PerkinElmer, Inc.
